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This audit was conducted to measure waiting times for systemic cancer therapy across the United Kingdom. All patients, aged
16 years or older, commencing their first course of systemic therapy between 13 November and 19 November 2006 were eligible
for inclusion. Data on 936 patients from 81 hospital sources were collected. Systemic therapy is largely given in compliance with
national waiting time targets. In terms of the Joint Council for Clinical Oncology (JCCO) targets, 84% of patients commence
treatment within 21 days and 98% of patients complied with the Department of Health target that treatment should follow within
31 days of the decision being agreed with the patient. Only 76% complied with the Department of Health 62-day target from GP
referral to first definitive treatment. However, the date of urgent referral by the GP was not submitted for most patients in our
survey, leaving a sample of only 84 out of 936 patients (9% of total) suitable for this analysis. There was only a 3- to 5-day difference
between the waiting times for systemic therapy for patients categorised as urgent compared with routine. Locally agreed definitions
had little impact on patients’ priority for treatment. This audit has established a baseline measurement of waiting times for systemic
therapy across the United Kingdom. The continuing introduction of novel therapies is likely to have a significant effect on the service
and we recommend that service managers model the likely impact on resource requirements. In addition, urgent treatment should be
clearly defined as that required within 24h (maximum 48h) to avoid the risk of clinical deterioration, particularly in patients with
acute leukaemia, lymphoma or germ cell tumour.
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It is commonly estimated that demand for systemic therapy
is increasing between 5 and 10% a year. Figure 1 shows data
for a single centre obtained over 15 years. It can be seen that
there was a continual increase in day case activity at 15% per year.
This includes supportive treatments such as transfusion and
bisphosphonate infusion. There are more limited data for
chemotherapy procedures and this activity increased at 5% per
year. The picture is complicated because these are data from a
major cancer centre where there has been continual change in
practice as chemotherapy services were developed at associated
cancer units.
With the continual increase in systemic therapy activity,
it might be anticipated that a mismatch with demand could
arise. This might then result in the development of waiting
times for treatment. An audit of 5750 women treated for breast
cancer in 1997–2000 to assess the effect of government targets
on the treatment of breast cancer showed that the percentage
of cases treated within 5 weeks was 78% for surgery, 53%
for radiotherapy and 81.2% for chemotherapy (Robinson et al,
2003). An audit of 342 patients treated for lung cancer showed
that the median wait for surgery, radiotherapy and chemotherapy
was 25, 43 and 16.5 days, respectively (Devbhandari et al,
2007). There are also regional data from Canada on waiting
times for chemotherapy (Cancer Care Ontario, 2007; Rayson
et al, 2007), but we are not aware of any previous UK national
audits to assess this problem. A search of the Medline
database using the terms ‘cancer’, ‘chemotherapy’, ‘systemic’,
‘therapy’, ‘times’ and ‘waiting’ identified no other relevant
publications.
Targets for cancer treatment were set in 1993 by the Joint
Collegiate Council for Oncology (JCCO) (Joint Collegiate Council
for Oncology, 1993). This is a joint body between The Royal
College of Radiologists and the Royal College of Physicians of
London. Recommended waiting time targets from the date of first
oncology consultation to the start of radiotherapy or chemother-
apy were as follows:
 For urgent radiotherapy or chemotherapy
* Good practice – 24h
* Maximum acceptable –48h
 For intensive (radical) chemotherapy
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s* Maximum acceptable – 3 weeks (where additional specialist
staging procedures are necessary).
The JCCO targets were set on the basis of professional opinion
(grade D recommendation). A search of the Medline database
using the terms ‘chemotherapy’, ‘delay’, ‘systemic’ and ‘therapy’
identified a single publication showing an impact of delay on
outcomes (Hershman et al, 2006). In a study of 5003 women aged
65 years or more with breast cancer, an interval between surgery
and chemotherapy of more than 3 months was associated with
increased mortality and disease-specific mortality. The authors
concluded that among older patients, moderate delays in the
receipt of adjuvant chemotherapy occur frequently, but long delays
(43 months) are uncommon. While early initiation of therapy is
of no benefit, significant delays are associated with increased
mortality. Whether this reflects the medical impact of the delay of
chemotherapy or factors associated with delay is unclear, but until
this is clarified, patients should be encouraged to initiate treatment
without significant delay (Hershman et al, 2006).
Anecdotally, unplanned delays in administering chemotherapy
are unusual. This is in stark contrast to the situation in
radiotherapy where over the last 20 years the continuing increase
in demand, not matched by a compensatory increase in treatment
capacity, has resulted in inevitable waiting lists (Williams et al,
2007). This is confirmed by the results of audits in breast and lung
cancer described above (Robinson et al, 2003; Devbhandari et al,
2007). A recent systematic review of delays in radiotherapy has
concluded that there is no threshold below which delay is safe and
that radiotherapy should be administered as soon as reasonably
achievable (Chen et al, 2008). This conclusion also seems
reasonable for systemic therapy but there is no evidence to
support it.
In United Kingdom, the NHS Cancer Plan laid out waiting time
targets that have now been fully implemented (Department of
Health, 2000). These comprise the following:
 A 31-day target: the interval from the date on which treatment
has been agreed with the patient (date of decision to treat
(DDT)) to first definitive treatment (FDT) for cancer therapy
should not exceed 31 days.
 A 62-day target: the interval from urgent GP referral to first
definitive treatment should not exceed 62 days.
These Department of Health targets only apply to a subset of
patients, as they must have been referred urgently by their GP and
be receiving their first definitive treatment for cancer. The present
audit was conducted to obtain a nationwide baseline of waiting
times across the four countries of the United Kingdom for systemic
therapy and to compare it with the standards set by the JCCO and
the Department of Health.
MATERIALS AND METHODS
In the United Kingdom, there are 203 acute NHS trusts, some of
which encompass several hospital sites. It is estimated that
chemotherapy is provided to patients at approximately 160 of
these hospitals (James, 2006), but there is no central database.
Systemic therapy for cancer can be given at any hospital, which
can obtain suitably formulated drugs for oral or intravenous use
and arrange for their administration in compliance with the Peer
Review Cancer measures (Department of Health, 2004). In
addition, there is independent sector provision.
We planned to undertake an audit of waiting times for systemic
therapy for cancer across the United Kingdom. To maximise
participation, members of the following organisations were asked
to disseminate information about participation in the audit to
heads of oncology services at hospitals offering systemic therapy:
(a) The Royal College of Radiologists (clinical oncology audit
leads).
(b) The Association of Cancer Physicians.
(c) The Cancer Network Pharmacists Forum.
(d) All Cancer Networks in England, Scotland and Wales.
All patients, aged 16 years or older, commencing their first
course of systemic therapy during a 1-week period between 13
November and 19 November 2006 were eligible to be included.
Systemic therapy included cytotoxic chemotherapy, antibody
therapy and targeted small molecule therapy, whether given orally
or intravenously. Hormonal therapy was excluded. The course of
treatment included in the audit might have been the patient’s first
definitive treatment for cancer or it could have been treatment
following on from radiotherapy or surgery. Prior systemic therapy
was an exclusion criterion.
Data were collected using two online data collection tools (one
for hospital demographic data, the other for waiting times data)
between 13 November 2006 and 31 January 2007 inclusive. The
tools, which had been piloted before national rollout, were
designed using Snap Survey Software (Version 8), and the data
were analysed using Microsoft Office Excel 2003 and Confidence
Interval Analysis (Version 2.1.2).
Appendix 1 shows the data collection tool that was designed to
obtain information about the diagnosis by tumour type and the
regimen administered. Waiting list status was classified by each
centre according to local definitions of priority (emergency within
24h, urgent and routine). Treatment intent was categorised into
curative, which included adjuvant therapy, palliative or concurrent
radiotherapy/chemotherapy. In discussing the results, the cate-
gories ‘curative’ and ‘radiotherapy/chemotherapy’ were combined
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Figure 1 Day case and chemotherapy work load over 15 years at a large
NHS teaching hospital Trust. Day case activity increased at 15% per annum
and chemotherapy at 5% per annum.
Table 1 Response rate of trusts submitting patient data classified by
country and by teaching or non-teaching status
Country
Response
rate % (n/N)
Response rate for teaching/
university trusts % (n/N)
United Kingdom 36 (61/171) 45 (13/29)
Scotland 21 (3/14)
a
Wales 46 (6/13)
Northern Ireland 20 (1/5)
aThe four Scottish hospitals that responded were drawn from 3 out of 14 NHS
boards.
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Treatment dates were also collected and a detailed specification of
national guidance defining these was made available, together with
the relevant web links.
As there were a number of outliers, waiting times data were
described using the median and interquartile range (IQR). To
compare differences in waiting times between subgroups, the
Wilcoxon two-sample test was used. This is equivalent to the
Mann–Whitney U-test.
RESULTS
Data were collected on 936 patients from 81 individual
and combined hospital sources (e.g,, multihospital NHS trusts).
In terms of the geographical distribution of the hospital
sources that submitted waiting times data, 76 (94%) were in
the United Kingdom or Wales, 4 (5%) were in Scotland and 1 (1%)
in Northern Ireland (see Table 1). The 76 UK and Welsh hospitals
were drawn from 67 out of 184 acute NHS trusts in the
two countries. However, not all acute trusts offer chemo-
therapy. Of these, 13 (19%) trusts represented were teaching
or university trusts (For the purpose of this audit, a teaching/
university trust was defined by ‘teaching’ or ‘university’ in
the title of the organisation.) and the proportion is similar
(14% among those who did not submit data). Figure 2 shows
that there does not appear to be a bias towards any particular
parts of the United Kingdom and Wales with regard to
participation.
Figure 3 shows that the most frequent diagnosis was breast
cancer, followed by colorectal and lung cancer. Figure 4 shows that
intravenous chemotherapy comprises the most frequent category
of systemic therapy at 85%. Treatment intent was curative
(including adjuvant) in 38%, palliative in 49% and don’t know in
Teaching/University Trust – data received
Teaching/University Trust – data not received
Other Acute Trust – data received
Other Acute Trust – data not received
NHS
Geographical distribution of Acute NHS Trusts in England and Wales and
whether or not waiting times data from hospitals in these trusts were received
NATCANSAT
www.canceruk.net
0870 840 8033
London
Figure 2 Geographical distribution of acute NHS trusts in the United Kingdom and Wales categorised by whether or not waiting times data were
received.
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Figure 3 Diagnostic categories.
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Figure 4 Treatment categories.
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s8%. Chemo/radiotherapy was administered to 6%, making a total
of 44% treated radically.
In terms of waiting list status, 1% of cases (8) were emergencies,
27% (252) were urgent, 48% (445) were routine and 25% (231)
were unknown. Forty-one per cent (388) of treatments were FDT.
Fifteen per cent (141) of all treatments were subject to elective
delay. The reasons given for elective delay (140) (One of the data
was missing.) were recovering from surgery (18%; 25), patient
request (19%; 26), intercurrent illness (9%; 13), don’t know (1%; 2)
and other (53%; 74). Elective delays were excluded from further
calculations.
Figure 5 shows waiting times for treatment categorised by
treatment intent and by waiting list status. Overall, there is only a
small improvement in the rapidity of treatment for those
categorised as urgent rather than routine. The median waiting
time from first oncology consultation to the start of urgent
chemotherapy was 9 days (IQR 16 days) and from first oncology
consultation to the start of routine chemotherapy was 12 days (IQR
11 days) (Figure 5A). Patients categorised as requiring urgent
palliative therapy were treated fastest (Figure 5B). Waiting times
by treatment intent and by waiting list status are shown in Table 2.
Patients in the urgent category were treated between 3 and 5 days
sooner. These differences in median waiting times were significant
for overall and for radical cases, but not for palliative cases using
the Wilcoxon two-sample test (Figure 5).
Figure 6 shows the results in terms of the Department
of Health’s 31-day and 62-day targets (Department of Health,
2000). The median time from DDT to FDT was 9 days (IQR
9 days) and from urgent GP referral to FDT 38 days (IQR 37 days).
Table 2 shows compliance with the treatment targets as
defined by Joint Collegiate Council for Oncology (1993) and
by the Department of Health (2000). Achievement of the
Department of Health 31-day target was 98.1%. Performance on
the 62-day target is less satisfactory at 76.2%. The JCCO target
that radical chemotherapy should start within 21 days was met
in 83.7% of cases, but the recommendation that urgent treat-
ment should start within 2 days was only met in 23.4% of cases
(Table 3).
Figure 7 shows the results for individual hospital units ranked in
order and identified by their individual code number. The varying
numbers in each chart reflect the number of patients in the
different categories. For the 62-day target, there were 320 patients
whose systemic therapy was their FDT and who were not subject to
elective delay. However, the date of urgent referral by the GP was
only available on 84 patients (26%). Lack of the appropriate data
probably influenced the apparently low achievement of the 62-day
target, with only 61% (20 of 33) of hospitals achieving it for all
patients, compared with 93% (66/71) for the 31-day target. There
was poor compliance with the JCCO target that urgent treatment
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Figure 5 Waiting times from date treatment plan agreed with patient to first administration of systemic therapy by treatment intent and waiting list status.
Table 2 Median waiting times from date treatment plan agreed with
patient to first administration of systemic therapy showing treatment intent
and waiting list status
Waiting list status
Urgent Routine
Treatment
intent % (n/N) M (days) % (n/N) M (days) P-value
All
a 38.3 (222/580) 9 61.7 (358/580) 12 0.01169
Radical
b 40.9 (106/259) 10.5 59.1 (153/259) 13 0.00884
Palliative 36.1 (100/277) 7 63.9 (177/277) 12 0.06072
a‘All’ comprised radical, palliative and don’t know.
bRadical comprised concurrent
radiotherapy/chemotherapy and curative (includes adjuvant).
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sshould be given within 48h, with only 10 hospitals (19%) achieving
it for all their patients.
DISCUSSION
We report a first attempt to measure waiting times for systemic
therapy for cancer across the United Kingdom. We received data
from 81 individual and combined hospital sources and estimate
that this comprised about half of trusts administering such
treatment to patients. Every effort was made to keep non-
responses to a minimum, by asking for small amounts of data,
and several mechanisms were used to disseminate the data
collection tools as widely as possible. The data were checked to
ensure that we had not received duplicate responses from the same
trust.
These data provide a snapshot of current workloads from a
sample of over half of the trusts administering such treatment.
These data were not population based, and it was not possible to
determine whether or not case ascertainment was complete in the
trusts that did submit data. However, previous national audits of
radiotherapy waiting times have shown good concordance between
data collected in a 1-week snapshot and large national data sets
(Williams et al, 2007). In that survey in 2005, 1 week’s data from all
57 radiotherapy centres in the United Kingdom was compared
with a sample of activity for the financial year 2004/05 for 36
English centres. The estimates of annual activity agreed within 3%
for patients and 6% for treatment fractions (Williams et al, 2007).
The cause of variable waiting times for treatment was not
identified in this audit, as we did not attempt to subdivide the wait
according to the intervals between the first oncology consultation,
the decision to treat and treatment delivery. This might be a topic
for local audit to identify where delays occur. No analysis of a
possible association between long waiting times and clinical or
epidemiological characteristics was attempted. As 84% of patients
were treated within 21 days, any such issues could be resolved by
local prioritisation.
The impact of delays will vary according to patient diagnosis; a
short delay or interruption between treatment courses could be
critical in the management of a rapidly proliferating leukaemia,
lymphoma or germ cell tumour but would be expected to have
much less impact on slower growing malignancies. In addition, we
only looked at the delay in commencing the first definitive
systemic therapy treatment. We did not analyse interruptions to
treatment later in the course that may also be critically important
for some subsets of patients. This paper presents no data on
outcomes as this would require long-term follow-up of individual
patients and we did not collect patient identifiable data centrally.
Figures 3 and 4 show the comparative frequency of different
malignancies and of different systemic therapies. The latter are
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Figure 6 Waiting times for the Department of Health 31-day target (DDT to FDT) and 61-day target (urgent GP referral to FDT).
Table 3 Compliance with targets
Targets
%( n/N) compliance
with target 95% CI
1. First oncology consultation to start of
urgent chemotherapy p2 days
23.4 (52/222) 18.3–29.4
First oncology consultation to start of
curative chemotherapy p21 days
83.7 (273/326) 79.3–87.4
DDT to FDT p31 days 98.1 (311/317) 96.4–99.0
Urgent GP referral to FDT p62 days 76.2 (64/84) 67.8–83.0
The discrepancy between radical cases (259) in Table 2 and curative in Table 3 arises
because the waiting list status (urgent/routine) was not recorded for 67 cases.
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sdominated by chemotherapy at 85% (Figure 4). Even within this
category, there are substantial variations in administration time.
Simple bolus chemotherapy may be administered in 30min, but
many drugs take longer time. For example, docetaxel takes an
hour, paclitaxel takes 3h and cisplatin takes 8h with the associated
necessary intravenous hydration. Antibody therapy shows a
similar spectrum of administration time. Rituximab takes 4h
for a first administration but can be shortened for subsequent
doses. Trastuzumab takes 90min with observation for the rest of
the day but subsequent infusions are given in 30min. The length of
time for which a patient is on treatment, particularly in the
metastatic setting, may be very prolonged, possibly even for years,
thereby adding to the long-term workload for a systemic therapy
unit.
It is important to note that many of the newer targeted
therapies, such as small-molecule tyrosine kinase inhibitors, are
given orally and the workload for administration will therefore be
low, although patient assessment and safety monitoring may be
more complex. There are therefore very substantial variations in
medical, nursing and couch-time resource implications for
patients receiving systemic therapy, which are not fully identified
in our audit.
Five-year survival of cancer in Europe continues to improve, but
in the United Kingdom survival for all cancers combined remains
below the European average, similar to that of some eastern
European countries (Verdecchia et al, 2007). Late diagnosis has
been highlighted as a major remediable cause of poor outcomes
(Richards, 2007), but underinvestment in cancer drugs may also
contribute (Anonymous, 2007). Practise will continue to change as
new agents become available, and as more lines of therapy are
offered to patients for a wider range of cancers and to patients who
are older and of lower performance status. In addition, there are
national initiatives to provide cancer services nearer to the
patient’s home and ambulatory care is highlighted in the Cancer
Reform Strategy (Department of Health, 2007a). The issues of
service planning are being addressed in the C-PORT initiative led
by the Cancer Action Team at the Department of Health (Cancer
Action Team, 2006). This provides a resource planning tool for
departments administering systemic therapy to cancer patients.
Figure 5 and Table 2 show that there is, in practise, little
distinction in the waiting time to start treatment between the JCCO
categories of urgent and routine, as currently self-defined by
departments across the United Kingdom. The poor compliance
with the JCCO target that urgent treatment should be given within
48h probably reflects inappropriate categorisation, as 38% of all
patients were so categorised (Table 2). We suggest that urgent
systemic therapy should be defined as that required within 24h
(maximum 48h) to avoid the risk of clinical deterioration,
particularly in patients with acute leukaemia, lymphoma or germ
cell tumour.
Performance across the United Kingdom against the Depart-
ment of Health 31-day and 62-day targets shows that there is high
compliance with the 31-day target at 98.1% of patients. The result
for the 62-day target is less satisfactory at 76.2%, on a sample of
only 84 out of 936 patients (9% of total), and 74% of otherwise
eligible cases were excluded because the date of urgent referral by
the GP was not submitted in our survey. The Department of Health
cancer waiting times database for the United Kingdom for the
same period (quarter 4, 2006/7) includes a much larger sample of
4538 patients treated both with chemotherapy and with hormones,
which were excluded from our study (Department of Health,
2007b). For the administration of these anti-cancer drugs, there
was 96% compliance when only a single trust was involved and
91% compliance where inter-trust transfers were involved (Di
Riley, Cancer Action Team, personal communication), for an
overall result of 96% compliance (Department of Health, 2007b).
Urgent treatment
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Figure 7 Percentage treated within target. Hospital reference numbers are shown along the X-axis.
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sFurther analysis would be required to determine the cause of the
discrepancy, but these results are not necessarily incompatible
with each other. The strength of our study, however, was that it
also included the 66% of patients who are not measured by
this target.
CONCLUSION
This audit has established a baseline measurement of waiting times
for systemic therapy across the United Kingdom. The continuing
introduction of novel therapies will have a significant effect on the
demands on the service. We recommend that service managers
model the likely impact on resource requirements, possibly using
the C-PORT tool being developed by the Department of Health
(Cancer Action Team, 2006). In addition, urgent treatment should
be clearly defined as that required within 24h (maximum 48h) to
avoid the risk of clinical deterioration, particularly in patients with
acute leukaemia, lymphoma or germ cell tumour.
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